BPC-157 is a lab-made peptide — a short chain of amino acids, the building blocks that make up proteins. Its name stands for "Body Protection Compound," and its recipe is copied from a protein our own stomachs produce1. In animal studies it keeps showing up as a healing helper, especially for tendons and gut tissue. But here's the part most websites skip: almost all of that evidence is in rats and cells, not people — and it is not an approved medicine.
In plain terms: genuinely interesting in the lab, still basically untested in humans.
What it's made of
BPC-157 is exactly 15 amino acids long — chemists call that a "pentadecapeptide" (penta-deca = fifteen). Three of those building blocks in a row are the amino acid proline, and that little detail matters: proline makes the peptide tough. Unlike most peptides, BPC-157 survives the harsh, acidic soup of the stomach instead of being broken apart1. That durability is a big reason scientists found it worth studying in the first place.
How it's thought to work
The leading idea comes from a 2017 study: BPC-157 appears to switch on a receptor called VEGFR2. Think of VEGFR2 as an "on switch" for angiogenesis — the growth of new blood vessels. More blood vessels means more oxygen and nutrients reaching injured tissue, which is exactly what healing needs. In the study, treated animal tissue grew more new vessels than untreated tissue5.
In plain terms: it may help the body build new plumbing to an injury. Important caveat — this mechanism was seen in animals and cells, so treat it as a strong *lead*, not a proven human effect.
What the studies actually found
Most of BPC-157's reputation rests on a run of rat "injury-and-repair" experiments across different tissues. Here are the notable ones in order, with the model each used — so you can see how the picture built up over 30 years:
| Study | Model | What happened | Year |
|---|---|---|---|
| Sikirić et al.1 | Rat (stomach) | Protected the gut lining from ulcers; first described the peptide's stability | 1993 |
| Staresinic et al.2 | Rat (cut Achilles tendon) | Faster, stronger tendon healing — higher load-to-failure and better collagen; also grew tendon cells in a dish | 2003 |
| Novinscak et al.3 | Rat (crushed calf muscle) | Faster muscle recovery and more muscle protein at days 7 and 14; less oxidative stress at the injury | 2008 |
| Cerovecki et al.4 | Rat (cut knee ligament) | Improved ligament healing over 90 days after surgery | 2010 |
| Hsieh et al.5 | Rat + cells (blood-flow injury) | More new blood-vessel growth via the VEGFR2 "on-switch" | 2017 |
| Vasireddi et al. — review7 | Review of all studies | Of 544 papers screened, only 1 was a human study | 2025 |
The pattern is consistent: cut, crush, or damage a tissue in a rat, give BPC-157, and it tends to heal faster and stronger than in untreated animals. The tendon study is the one that made it famous — a surgically cut Achilles tendon healed into a physically stronger repair2. That's a genuinely encouraging signal. It is also, so far, almost entirely a *rat* signal.
Beyond tendons: the gut
Before the tendon and muscle work, BPC-157's original story was the gut. The earliest studies described it protecting the stomach and intestinal lining from ulcers and damage1 — which fits its origin as a fragment of a stomach-protective protein. Much of the later research treats "body protection" as a general tissue-repair theme rather than one specific to any single organ.
Why "how long it lasts" is confusing
BPC-157 has a quirk worth knowing: it clears from the blood quickly, yet its effects in studies seem to last longer than the blood level alone would suggest. So a half-life curve tells you how long the compound *stays in the blood* — not how long it *keeps working*. We unpack this gap in BPC-157's half-life explained.
Is it legal? Regulatory status
This is where a lot of people get confused, so plainly: BPC-157 is not an approved drug anywhere, and in the United States its status recently got stricter. In 2023 the FDA placed BPC-157 (along with several other research peptides) in "Category 2" on its list of bulk substances for compounding pharmacies — a label that essentially means "don't compound this," citing safety questions and a lack of clinical data6. In practice that has made legitimate pharmacy access much harder in the US. This page takes no position on where anyone obtains anything and never discusses sourcing — it's simply the regulatory reality worth knowing.
Latest research (2025–2026)
The picture is actively moving, which is part of what makes BPC-157 interesting right now:
- The 2025 systematic review (above) is the most rigorous stock-take to date, and its blunt conclusion — 35 animal studies, 1 human study out of 544 papers — is the current state of the evidence7.
- First small human safety reports began appearing in 2025. These are early, tiny, and uncontrolled — a long way from proof that it *works* — but they mark the first movement of BPC-157 research from animals toward people.
- Regulatory review continues. The FDA's compounding advisory committee has scheduled further evaluation of these peptides, so the compounding status could change again6.
We keep this section current as new studies land — the freshest accurate picture is the point.
The honest bottom line
BPC-157's story is a run of consistent, encouraging *animal* results — tendon, muscle, ligament, and gut — tied together by a plausible blood-vessel-growth mechanism. But two facts keep it honest:
- Most of it comes from one lab. A large share of the foundational work is from a single research group in Zagreb. Consistent results from one team aren't the same as being confirmed by others.
- No proper human trial has been finished. There's still no completed, placebo-controlled human study showing it works for anything, and its US compounding status is now restricted.
None of that makes the animal results boring — it means the *human* proof isn't there yet, and you deserve to hear that plainly.
The short version
BPC-157 is a durable little peptide with promising healing results across several rat-injury models and a sensible mechanism. It's a research compound, not a medicine; the human evidence is still almost empty, and it's now a restricted substance for US compounding. This page explains what it is and what studies show — not how to use it. For the bigger picture, see what are research peptides; it's most often compared with TB-500.